PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours

Single dose of GLYX-13 produced statistically significant reductions in depression scores within 24 hours in subjects who failed other therapies, with efficacy nearly double that of most antidepressants and no ketamine-like psychotomimetic effects

2012-12-06
(Press-News.org) HOLLYWOOD, FL and EVANSTON, IL, December 6, 2012 -- Naurex Inc., a clinical stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13. GLYX-13 is a novel partial agonist of the NMDA receptor. The Phase Ila results are being presented this week at the 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP).

The Phase IIa results show that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with one or more antidepressant agents. The reductions were evident within 24 hours and persisted for an average of seven days. Importantly, the effect size, a measure of the magnitude of the drug's antidepressant efficacy, observed at 24 hours and at seven days after a single administration of GLYX-13, was nearly double the effect size seen with most other antidepressant drugs after 4-6 weeks of repeated dosing.

In the Phase IIa trial, GLYX-13 was well tolerated. Reported side effects were mild to moderate and were consistent with those observed in subjects receiving placebo. Consistent with previous studies, GLYX-13 did not produce any of the schizophrenia-like psychotomimetic effects associated with other drugs that modulate the NMDA receptor.

"These data are an important step in validating Naurex's mission of developing breakthrough therapies for depression and other CNS disorders," said Derek Small, CEO of Naurex. "Our founder discovered a new class of drugs that appeared to have the remarkable antidepressant efficacy of ketamine-like compounds, but without their limiting side effects. These Phase II results suggest that this discovery may translate into measurable health improvements for individuals with depression, which bodes well for the future success of GLYX-13 and the other promising compounds we have generated from this platform."

Other NMDA receptor-modulating agents, such as ketamine, have been shown in several human clinical trials to act very rapidly to alleviate the symptoms of depression and bipolar disorder, but their clinical utility has been hampered by their potential for abuse and behavioral impairment, including schizophrenia-like effects at therapeutic doses.

"We are encouraged by these promising data," noted Ronald M. Burch, MD, PhD, Chief Medical Officer of Naurex. "We have recently begun dosing patients in a GLYX-13 Phase Ilb repeated dose trial, and we are on track to advance our second-generation oral compound, NRX-1074, into clinical trials next year. Preclinical studies show that our novel NMDA modulators may be applicable to a number of CNS disorders, and we look forward to assessing their potential to address major unmet needs in psychiatry and neurology."

The Phase Ila trial was a randomized, double blind, placebo-controlled study of the efficacy and safety of a single dose of intravenous GLYX-13 in subjects who had failed at least one other antidepressant during the current depressive episode. It was conducted at 12 clinical centers in the U.S. Outcome measures included ratings of signs, symptoms and changes in depression scores on standard rating scales for mood and psychiatric disorders. Independent raters from MedAvante, who were blinded to the protocol, administered certain psychiatric assessments for the trial to ensure the quality and objectivity of the screening and rating data. Safety was also assessed.

### Naurex's CNS programs are based on the work of company founder, Joseph R. Moskal, PhD, and his colleagues at the Falk Center for Molecular Therapeutics at Northwestern University.

The 51st Annual Meeting of the American College of Neuropsychopharmacology is being held December 2-6, 2012 in Hollywood, Florida. For more information, visit www.acnp.org/annualmeeting/default.aspx.

About Naurex Naurex Inc. is a clinical stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor in a safe way. Naurex's lead product, GLYX-13, has shown promising antidepressant activity with excellent safety in a Phase II trial, confirming the efficacy signals and safety observed in Phase I and preclinical studies. In a Phase II trial in subjects who had failed treatment with one or more antidepressant agents, a single administration of GLYX-13 produced statistically significant reductions in depression scores within 24 hours, which persisted for an average of seven days. Naurex's second-generation programs include a number of molecules with preclinical proof of concept. The company's patented novel chemistry classes represent a platform for the development of new therapies for a variety of CNS disorders. For more information about Naurex, visit www.naurex.com.


ELSE PRESS RELEASES FROM THIS DATE:

Research yields understanding of Darwin's 'abominable mystery'

2012-12-06
Research by Indiana University paleobotanist David L. Dilcher and colleagues in Europe sheds new light on what Charles Darwin famously called "an abominable mystery": the apparently sudden appearance and rapid spread of flowering plants in the fossil record. Writing in the Proceedings of the National Academy of Sciences, the researchers present a scenario in which flowering plants, or angiosperms, evolved and colonized various types of aquatic environments over about 45 million years in the early to middle Cretaceous Period. Dilcher is professor emeritus at IU Bloomington ...

Environmental chemical blocks cell function

2012-12-06
Bisphenol A, a substance found in many synthetic products, is considered to be harmful, particularly, for fetuses and babies. Researchers from the University of Bonn have now shown in experiments on cells from human and mouse tissue that this environmental chemical blocks calcium channels in cell membranes. Similar effects are elicited by drugs used to treat high blood pressure and cardiac arrhythmia. The results are now presented in the journal "Molecular Pharmacology." The industrial chemical bisphenol A (BPA) is worldwide extensively utilized for manufacturing polycarbonates ...

New evidence for epigenetic effects of diet on healthy aging

New evidence for epigenetic effects of diet on healthy aging
2012-12-06
New research in human volunteers has shown that molecular changes to our genes, known as epigenetic marks, are driven mainly by ageing but are also affected by what we eat. The study showed that whilst age had the biggest effects on these molecular changes, selenium and vitamin D status reduced the accumulation of epigenetic changes, and high blood folate and obesity increased them. These findings support the idea that healthy ageing is affected by what we eat. Researchers from the Institute of Food Research led by Dr Nigel Belshaw, working with Prof John Mathers and ...

New understanding can lead to srategies for dealing with neurodegenerative diseases

New understanding can lead to srategies for dealing with neurodegenerative diseases
2012-12-06
Jerusalem Dec. 6, 2012 – A new understanding of what takes place on the cellular level during the development of neurodegenerative diseases, such as Parkinson's, Alzheimer's, ALS and Huntington's diseases, offers promise towards possible new strategies for combating such diseases, say Hebrew University of Jerusalem researchers. Neurodegenerative conditions result from an impairment of motor function or cognitive function or both. This impairment results from degeneration in the particular area of the brain responsible for those functions. Although these neurodegenerative ...

'Releasing' people from Catholic guilt increases generosity towards church, research shows

2012-12-06
People who recall being absolved of their sins, are more likely to donate money to the church, according to research published today in the journal Religion, Brain and Behavior. Researchers from Royal Holloway and the University of Oxford assigned participants two memory tasks. In the first, they were asked to privately recall a sin that they had committed in the past, while in the second, they recalled attending confession for this sin or imagined doing so, if they had not confessed in reality. Each participant was also given an opportunity to donate to a local Catholic ...

My microbes

2012-12-06
We all have E.coli bacteria in our gut but each of us carries a version that is genetically slightly different. The same can be said of most gut microbes: our own gut metagenome, that is the sum of all the genomes of all our gut microbes, appears to be really specific to each of us, and to remain stable over time. For the first time, researchers from the European Molecular Biology Laboratory (EMBL) have studied this metagenome at such a high resolution that individual mutations in the various strains could be analysed. Their findings, published today in Nature, could have ...

Insight into DNA reprogramming during egg and sperm cell development

2012-12-06
Scientists at the Babraham Institute have gained a new understanding of when and how the DNA in developing egg and sperm cells is 'reset', in preparation for making a new embryo. It is well known that small chemical groups can be added to DNA to alter gene activity, these modifications to the DNA are acquired during development in the womb and throughout adult life and can arise from changes in environment. Most of these modifications are removed in immature egg and sperm cells to 'reset' the DNA and to erase any 'environmental memory', but some remain. Decoding this reprogramming ...

Cocktail boosts immune cells in fighting cancer

2012-12-06
Fighting cancer using the body's own defense system is a promising treatment approach. Immune therapies have even become clinical routine in treating a few cancers such as malignant melanoma and prostate cancer. Natural killer cells (or NK cells) are considered to be particularly suitable weapons against cancer. They are part of the innate immune system and respond to a wide range of cancer cells of diverse origin. Moreover, NK cells also kill tumor cells that have lost a specific target and go unnoticed by other immune cells. "The big problem in using NK cells for therapy ...

Warm sea water is melting Antarctic glaciers

2012-12-06
The ice sheet in West Antarctica is melting faster than expected. New observations published by oceanographers from the University of Gothenburg and the US may improve our ability to predict future changes in ice sheet mass. The study was recently published in the journal Nature Geoscience. A reduction of the ice sheets in Antarctica and Greenland will affect the water levels of the world's oceans. It is therefore problematic that we currently have insufficient knowledge about the ocean circulation near large glaciers in West Antarctica. This means that researchers ...

Feeling disgust may enhance our ability to detect impurities

2012-12-06
Disgust – it's an emotion we experience when we encounter things that are dirty, impure, or otherwise contaminated. From an evolutionary standpoint, experiencing the intense, visceral sense of revulsion that comes with disgust presumably helps us to avoid contaminants that can make us sick or even kill us. But new research suggests that disgust not only helps us to avoid impurities, it may also make us better able to see them. If something looks dirty and disgusting, we typically assume it's contaminated in some way; when something is white, however, we are more likely ...

LAST 30 PRESS RELEASES:

Are lifetimes of big appliances really shrinking?

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Study links teen girls’ screen time to sleep disruptions and depression

Scientists unveil starfish-inspired wearable tech for heart monitoring

Footprints reveal prehistoric Scottish lagoons were stomping grounds for giant Jurassic dinosaurs

AI effectively predicts dementia risk in American Indian/Alaska Native elders

First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

Existing international law can help secure peace and security in outer space, study shows

Pinning down the process of West Nile virus transmission

UTA-backed research tackles health challenges across ages

In pancreatic cancer, a race against time

[Press-News.org] ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
Single dose of GLYX-13 produced statistically significant reductions in depression scores within 24 hours in subjects who failed other therapies, with efficacy nearly double that of most antidepressants and no ketamine-like psychotomimetic effects